Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results

Stock Track

07/10

Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.

The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.

Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1128639414"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128639414\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128639414?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128639414","market":"us","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results","media":"Stock Track","content":"<p>Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.</p><p>The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.</p><p>Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-07-10 11:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.</p><p>The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.</p><p>Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1128639414","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128639414","pubTimestamp":1783653296,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.The biotech company announced that its Ryoncil product delivered net...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"股票跟踪 | 由于 Ryoncil 强劲的收入业绩，Mesoblast 盘中飙升 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}